NewsRoom Articles - Page 65 of 154 - PsychedelicNewsWire (PNW)

FridayMar 18, 2022 3:46 pm

Psychedelics Industry Sees Huge Interest from Pharmaceutical Sector Players

Various companies and experts are hailing psychedelics such as MDMA, LSD and psilocybin, as well as mind-altering substances such as ketamine, as the next revolutionary treatment for a number of mental health conditions. The surge in the popularity of psychedelic substances started almost a decade ago, with different research groups at the University of Zurich, Imperial College London, New York University, Johns Hopkins University and the University of California discovering the rapid and lasting effects of using psychedelics, including psilocybin, to treat small groups of individuals with existential distress and treatment-resistant depression. The results from these studies broke the model…

FridayMar 18, 2022 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences

Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and…

ThursdayMar 17, 2022 1:11 pm

Study Suggests That MDMA Therapy for PTSD May Save Millions in Healthcare Costs

A new study has found that MDMA-assisted therapy may extend and improve the lives of patients suffering from severe and chronic PTSD and also decrease the cost of healthcare. MDMA is a drug known to alter an individual’s mood and perception; it is commonly referred to as molly or ecstasy. Elliot Marseille, the study’s corresponding author, stated that he launched the Global Initiative for Psychedelic Science Economics together with his colleagues from UC Berkeley and UCSF after seeing encouraging results on psychedelic-assisted therapy from different clinical trials. Marseille, who is also the founder of Health Strategies International, explained that the…

ThursdayMar 17, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Aiming to Reach Millions of Mental Health Patients with Effective, Affordable Ketamine Treatments

Mental health conditions affect millions of people globally, some of whom are resistant to existing treatments In the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatment Delic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes showing its therapeutic effectiveness Delic hopes to reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments The World Health Organization (“WHO”) reports that…

ThursdayMar 17, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention…

WednesdayMar 16, 2022 12:55 pm

Study Finds Psilocybin Microdosing Doesn’t Decrease Anxiety, Depression Symptoms

Various studies have found that regular psilocybin doses have long lasting and profound effects on an individual’s mood and personality. However, a new placebo-controlled study has discovered that consuming microdoses of psilocybin at regular intervals doesn’t improve symptoms of anxiety or depression. The study’s findings, which were reported in the “Journal of Psychopharmacology,” challenge claims that microdosing on psychedelics improves mental health. Preliminary studies have shown that microdosing psychedelics is linked to a range of psychological benefits, including decreased stress and increased productivity. However, most of the studies done on microdosing had limitations, the main one being a lack of…

WednesdayMar 16, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leverages Research to Promote Mental Health

Delic Holdings Corp, a leader in new medicines and treatments for a modern world, understands that research is integral for both the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for the treatment of mental health issues Dr. Markus Roggen, President and CSO of Delic Labs, recently spoke at this year’s Emerald Conference, and has reiterated the importance of leveraging AI in crafting products for the cannabis industry Delic is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products for more people, supporting mental health while…

TuesdayMar 15, 2022 1:56 pm

Giving Zebrafish Microdoses of LSD Reveals Therapeutic Potential

Zebrafish share about 70% of the same genes with humans and roughly 85% of human genes known to be linked to human diseases. This makes them a unique model animal for biomedical research, in addition to being social, which makes them suitable for behavioral research into drug discovery and psychiatric disorders. Researchers conducting studies on LSD are microdosing zebrafish in an effort to explore potential new treatments for alcohol use disorder and mental illness. Microdosing refers to ingesting small amounts of a psychedelic. It is believed that microdosing improves open-mindedness, sparks creativity and increases productivity. For their study, the researchers…

MondayMar 14, 2022 11:24 am

Missouri Legislator Files Measure to Decriminalize Psychedelics

Last week, a Missouri legislator filed a measure that would legalize an extensive range of psychedelic drugs for therapeutic use and decriminalize low-level possession in the state. The measure was sponsored by Republican lawmaker, Rep. Tony Lovasco. It is the latest example of psychedelic reforms being introduced in states that are traditionally conservative. The measure would provide patients suffering from conditions such as post-traumatic stress disorder treatment-resistant depression and other terminal illnesses with access to a wider range of substances including ibogaine, mescaline, DMT and psilocybin in a clinical setting. Patients will be allowed to access this treatment option at…

FridayMar 11, 2022 2:06 pm

Research Finds That Psilocybin Mushrooms May Help Treat Severe Depression

Psilocybin has been used for millennia around the globe for many uses, including for spiritual connections as well as a remedy in some Indigenous communities. Research has shown that this hallucinogenic compound found in “magic mushrooms” can be used to treat severe depression. However, since it was banned in 1970, psilocybin remains classified as a Schedule I substance under the Controlled Substances Act. Substances under this classification are considered to have a high potential for abuse with no accepted medical use. This isn’t the case for most substances under this classification, and as more research on psychedelics surfaces, this may…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000